PTO/SB/21 (05-03) 16 Z 4 003. OMB 0654

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/088,160 RECEIVED TRANSMITTAL Filing Date March 13, 2002 **FORM** Alexander KOZAK First Named Inventor DEC 0 8 5003 o be used for all correspondence after initial filing) **Group Art Unit** 1624 **Examiner Name** John M. Ford 1660/2986 TECH CENTER Total Number of Pages in This Submission Attorney Docket Number 25 800.1015 ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers Fee Transmittal Form (for an Application) Group Appeal Communication to Board of Fee Attached Drawing(s) Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) After Final Petition Proprietary Information Petition to Convert to a Affidavits/declaration(s) Status Letter **Provisional Application** Power of Attorney, Revocation Other Enclosure(s) Extension of Time Request Change of Correspondence Address (please identify below): - Return Receipt Postcard **Terminal Disclaimer** Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Davidson, Davidson & Kappel, LLC Name 485 Seventh Avenue, 14th Floor Address City New York State NY Zip Code 10018 (212) 736-1940 Country USA Fax Telephone (212) 736-2427 Individual name Morey B. Wildes Reg. No. 36,968 Signature December 2, 2003 Date CERTIFICATE OF TRANSMISSION/MAILING

Typed or printed name Patricia-Kane Signature Date December 2, 2003 This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

1450 on the date shown below:

complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Alexander KOZAK, et al.

Serial No.:

10/088,160

Filed:

March 13, 2002

For:

PHOSPHOLIPID PRODRUGS OF ANTI-

PROLIFERATIVE DRUGS

TECH CENTER 1600/2900

DEC 0 9 2003

Examiner:

John M. Ford

Art Unit:

1624

MAIL STOP: Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 December 2, 2003

RESPONSE TO OFFICE ACTION

SIR:

In response to the Office Action dated September 2, 2003 by the U.S. Patent and Trademark Office in connection with the above-identified application, Applicants hereby amend this application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims, which begins on page 11 of this paper.

Remarks begin on page 17 of this paper.